Brussels, Belgium, 30 may 2017, 18: 45 (CEST) ASIT biotech (Euronext : ASIT – BE0974289218), a biopharmaceutical company focused on the belgian stage of the clinical development specialized in the research, development and future commercialization of a new generation of immunotherapy products innovative for the treatment of allergies, will present at the EAACI congress (European Academy of Allergy and Clinical Immunology) the detailed results of the phase III clinical study conducted with gp-ASIT+, its product candidate for the treatment of allergic rhinitis to grass pollen. The congress will be held in Helsinki from 17 to 21 June 2017.
Download the free guide
Boost your gains
EAACI is the event of reference organized by the Academy and one of the largest international meetings devoted to the allergology and clinical immunology. It brings together thousands of specialists from around the world and offers concurrent sessions covering all aspects of the specialty of the Academy.
The two papers last minute (late breaking abstract) proposed by ASIT biotech have been selected by the review committee of the EAACI for an oral presentation :
Title : Efficacy of a 3-week subcutaneous immunotherapy race in patients with grass pollen-induced rhinoconjunctivitis: Results of a phase-3 study
Speaker : Pr. Dr. Ralph Mösges (University of Cologne)
Session : LB PDS 4 Allergen immunotherapy: Vaccines and clinical June 19, 2017 10: 45am
Type : Discussion post
Title : Short Course treatment of Subcutaneous Peptide Hydrolysate from Lolium Perenne suppresses Basophil Responses and induces IgG-associated Blocking Antibodies: A Randomized Double-Blind Placebo-Controlled Trial
Speaker : Dr. Mohamed Shamji (Imperial College London)
Session : LB OSA 5 Allergen Immunotherapy – mechanisms and vaccines June 21, 2017 10: 30am
Type : oral Presentation
***
About ASIT biotech
ASIT biotech is a biopharmaceutical company focused on the belgian stage of the clinical development specialist in the development and future commercialization of a new generation of immunotherapy products for allergies. Thanks to ASIT+, its innovative technological platform, ASIT biotech is currently the only developer of immunotherapies allergenic with a unique blend of fragments of allergens natural, highly purified, and of optimal size. The result of this innovation is a short-term treatment, which should improve the acceptance and adherence to treatment by patients and its effectiveness in real life. The portfolio ASIT biotech has two product candidates are innovative, targeting respiratory allergies, with the highest prevalence (allergies to grass pollens with gp-ASIT+ and dust mites with hdm-ASIT+). These products could expand significantly the current market for immunotherapy. Finally, the Company believes that its innovative platform ASIT+ is flexible and applicable to other types of allergies.
ASIT biotech has 22 employees and collaborators. Its head office is in Brussels and its laboratories in Liege, Belgium.
More information on www.asitbiotech.com.
Download the free guide
Boost your gains
